PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.
Sjogren’s Without Dryness? Yes, It’s a Thing
More than 10% of patients diagnosed with primary Sjögren’s syndrome at a French referral center reported little to no dryness in the mouth or eyes,
October 31, 2023